According to Swedish Orphan Biovitrum's latest financial reports the company has โน8.85 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2024-12-31 | โน8.87 B | 18.71% |
2023-12-31 | โน7.47 B | -31% |
2022-12-31 | โน10.83 B | 25.98% |
2021-12-31 | โน8.59 B | 138.28% |
2020-12-31 | โน3.60 B | -35.85% |
2019-12-31 | โน5.62 B | -75.91% |
2018-12-31 | โน23.35 B | 102.34% |
2017-12-31 | โน11.54 B | 96.28% |
2016-12-31 | โน5.87 B | -17.67% |
2015-12-31 | โน7.14 B | 68.26% |
2014-12-31 | โน4.24 B | -1.05% |
2013-12-31 | โน4.28 B | 11.46% |
2012-12-31 | โน3.84 B | 128.37% |
2011-12-31 | โน1.68 B | 559.61% |
2010-12-31 | โน0.25 B | -87.29% |
2009-12-31 | โน2.01 B | -28.82% |
2008-12-31 | โน2.82 B | -38.88% |
2007-12-31 | โน4.62 B | -21.04% |
2006-12-31 | โน5.85 B | -2.23% |
2005-12-31 | โน5.98 B | -12.45% |
2004-12-31 | โน6.83 B | 794.3% |
2003-12-31 | โน0.76 B | 31.23% |
2002-12-31 | โน0.58 B |